[Remote] Medical Science Liaison, Endocrinology – Mid-Atlantic Region at Corcept Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Skills

Key technologies and capabilities for this role

EndocrinologyCortisol ModulatorsGlucocorticoid Receptor (GR)Cushing's SyndromeMedical AffairsScientific CommunicationClinical AcumenThought Leader EngagementHealthcare Professional (HCP) EducationMedical InquiriesScientific Presentations

Questions & Answers

Common questions about this position

What is the travel requirement for this Medical Science Liaison role?

The position requires 70% travel.

What are the preferred skills for this MSL position?

Preferred skills include strong business acumen with working knowledge of multi-disciplinary drug development functions such as research, development, clinical operations, biostatistics, regulatory, and commercial, along with exemplifying core competencies.

What salary or compensation does this role offer?

This information is not specified in the job description.

What are the core responsibilities of the MSL in Endocrinology?

Responsibilities include engaging in scientific discussions with thought leaders and HCPs, providing presentations and educational programs, developing relationships with the medical community, responding to inquiries, reviewing literature, and supporting clinical trials and events.

What makes a strong candidate for this MSL role?

A strong candidate demonstrates strong clinical acumen, ability to engage in scientific discussions with thought leaders and HCPs, adherence to ethical standards, and the MSL Core Competencies, with expertise in endocrinology and Corcept’s therapeutic areas.

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free